Apertura Gene Therapy Launches Open Aperture, a Material Transfer Agreement Program to Facilitate Non-Commercial Access to TfR1 CapX for Academic Research…

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today ...
GEN

Solid Biosciences Licenses Use of Next-Generation Capsid AAV-SLB101 to Andelyn Biosciences

Solid Biosciences signed a gene therapy agreement with CDMO Andelyn Biosciences for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101. Solid grants Andelyn a non-exclusive worldwide ...